Connor, Clark & Lunn Investment Management (CC&L)
CDTX

Connor, Clark & Lunn Investment Management (CC&L)’s Cidara Therapeutics CDTX Stock Holding History

Connor, Clark & Lunn Investment Management (CC&L)’s Portfolio CDTX Stock Details CDTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-15,842
Closed -$291K – 1410
2024
Q1 		$291K Hold
15,842
– – ﹤0.01% 1277
2023
Q4 		$252K Sell
15,842
-618
-4% -$9.93K ﹤0.01% 1217
2023
Q3 		$310K Buy
16,460
+422
+3% +$8.28K ﹤0.01% 1133
2023
Q2 		$362K Buy
+16,038
New +$377K ﹤0.01% 1067
2022
Q1 		– Sell
-4,405
Closed -$112K – 1055
2021
Q4 		$112K Buy
4,405
+1,733
+65% +$54K ﹤0.01% 1026
2021
Q3 		$120K Buy
+2,672
New +$102K ﹤0.01% 972
2020
Q4 		– Sell
-988
Closed -$56K – 913
2020
Q3 		$56K Sell
988
-1,207
-55% -$85.2K ﹤0.01% 896
2020
Q2 		$162K Sell
2,195
-343
-14% -$22.2K ﹤0.01% 919
2020
Q1 		$126K Buy
2,538
+1,363
+116% +$81.7K ﹤0.01% 913
2019
Q4 		$90K Buy
+1,175
New +$53.8K ﹤0.01% 883

Other funds holding CDTX

MIM
Monashee Investment Management Boston, Massachusetts $59.6M AUM 181.61% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CC
Checkpoint Capital San Francisco, California $390M AUM 96.52% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
ACM
Alethea Capital Management Mercer Island, Washington $241M AUM 112.74% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $288M AUM 313.93% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $27.9B AUM 51.18% 1-Year Est. Return

Connor, Clark & Lunn Investment Management (CC&L)'s CDTX Position: Q2 2024 in Review

Connor, Clark & Lunn Investment Management (CC&L) sold out of Cidara Therapeutics (CDTX) in Q2 2024, closing a stake of 15,842 shares — an estimated $291K sold.

Connor, Clark & Lunn Investment Management (CC&L) first reported a position in CDTX in Q4 2019 and held it in 10 quarters. The position peaked at $362K in Q2 2023. 26 funds tracked by Wall St. Rank hold CDTX as of Q2 2024.

  • Connor, Clark & Lunn Investment Management (CC&L) reported no remaining Cidara Therapeutics position as of Q2 2024 after selling out during the quarter.
  • Connor, Clark & Lunn Investment Management (CC&L) sold 15,842 Cidara Therapeutics shares in Q2 2024, an estimated $291K.
  • Connor, Clark & Lunn Investment Management (CC&L) first reported a position in Cidara Therapeutics in Q4 2019 and held it in 10 quarters.
  • Connor, Clark & Lunn Investment Management (CC&L)'s Cidara Therapeutics position peaked at $362K in Q2 2023.
  • 26 funds tracked by Wall St. Rank held Cidara Therapeutics as of Q2 2024.

Based on Connor, Clark & Lunn Investment Management (CC&L)'s 13F filing for Q2 2024, filed 9 Aug 2024.